AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19589288
Drug: Nasal syringe
RxNorm normalized name: nasal syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal syringe (10 mL saline solution, 3 times daily for 14 days)
Trial: 1955814
Drug: Diazepam (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0 mg, 7.5 mg, 15 mg, 30 mg/70 kg, p.o.)
Trial: 1955814
Drug: Triazolam (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0 mg, 0.375 mg, 0.75 mg/70 kg, p.o.)
Trial: 8207316
Drug: Indobufen 200
RxNorm normalized name: indobufen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 200 mg twice daily
Trial: 7134226
Drug: Indobufen (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (higher dosage)
Trial: 27832646
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg folic acid (control group); n = 50
Trial: 25301018
Drug: Patient knowledge
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient knowledge of medical condition and treatment options
Trial: 22532053
Drug: Group interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group interpersonal psychotherapy (IPT-G)
Trial: 15161357
Drug: Chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chronic low-dose whole-body ionizing radiation exposure
Trial: 9546804
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) and didanosine (ddI) therapy
Trial: 10488481
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no therapy
Trial: 1707338
Drug: Concomitant radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant radiation therapy and chemotherapy (RT + CT) with 5‐fluorouracil (5‐FU), mitomycin C, and bleomycin
Trial: 7009256
Drug: Conventional oxprenolol
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional oxprenolol administered twice daily
Trial: 7009256
Drug: Slow-release oxprenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oxprenolol administered once daily
Trial: 7009256
Drug: Cyclopenthiazide 0.5
RxNorm normalized name: cyclopenthiazide 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopenthiazide 0.5 mg daily (in 16 patients)
Trial: 9709721
Drug: 7-valent pneumococcal-conjugate
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal-conjugate vaccine plus 23-valent pneumococcal vaccine
Trial: 9709721
Drug: 23-valent vaccine
RxNorm normalized name: Pneumococcal 23-valent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent vaccine only
Trial: 3276900
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with 5‐fluorouracil, semustine, and vincristine (MOF) (187 patients)
Trial: 3276900
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (4,600‐4,700 rad in 26‐27 fractions; 5,100‐5,300 rad maximum at the perineum) (184 patients)
Trial: 3276900
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (184 patients)
Trial: 21668683
Drug: Ann Arbor
RxNorm normalized name: Hemoglobin Ann Arbor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ann Arbor strain live attenuated influenza vaccine (LAIV)
Trial: 1401653
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg)
Trial: 8464431
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg once daily)
Trial: 1392444
Drug: Urodilatin (CDD/ANP‐95‐126)
RxNorm normalized name: CDDP
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urodilatin (CDD/ANP‐95‐126) administered in a long‐term, low‐dose infusion (6‐20 ng/kg bw.min) for 96 hours after HTx
Trial: 30987415
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization of 5 ml 1% ropivacaine before and after surgery
Trial: 30987415
Drug: Intraperitoneal instillation
RxNorm normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation of 20 ml 0.5% ropivacaine after induction of pneumoperitoneum
Trial: 30987415
Drug: Intraperitoneal nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal nebulization of 5 ml 1% ropivacaine
Trial: 25144296
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg and Candesartan cilexetil 32 mg
Trial: 25144296
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (any dose) and Candesartan cilexetil (any dose)
Trial: 25144296
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 20 mg and Candesartan cilexetil 4 mg
Trial: 9758086
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS monotherapy
Trial: 25144296
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS plus Candesartan cilexetil combination therapy
Trial: 20067715
Drug: Focused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused extracorporeal shock wave therapy (0.20 mJ/mm(2))
Trial: 20067715
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (0.17 mJ/mm(2))
Trial: 7494110
Drug: Prednisolone plus
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone plus a beta‐lactamase stable antibiotic for 10 days, with responders receiving an additional six weeks of chemoprophylaxis.
Trial: 7494110
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Control group).
Trial: 7494110
Drug: Prednisolone plus
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone plus a beta‐lactamase stable antibiotic.
Trial: 7439263
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of ketoprofen (capsule)
Trial: 7439263
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of ketoprofen
Trial: 7439263
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of ketoprofen (suppository)
Trial: 7439263
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of ketoprofen
Trial: 7439263
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral administration of ketoprofen (50 mg q.i.d.)
Trial: 7439263
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of ketoprofen
Trial: 31815790
Drug: New clinical
RxNorm normalized name: octinoxate 75 mg in 1 g / oxybenzone 40 mg in 1 g / avobenzone 20 mg in 1 g TOPICAL CREAM [Anew Clinical Absolute Even Spot Correcting Hand]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New clinical endpoints focusing on treatment safety and patient quality of life.
Trial: 28178008
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional cooling treatment (Control)
Trial: 25808994
Drug: CNI-free (everolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI-free (everolimus with half-dose EC-MPS 720 mg/day and cyclosporine withdrawal)
Trial: 23668026
Drug: Decoction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction of invigorating Qi and clearing lung combined with standardized myrtol (300 mg, 3 times a day)
Trial: 23668026
Drug: Standardized myrtol
RxNorm normalized name: myrtol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized myrtol (300 mg, 3 times a day)
Trial: 21030470
Drug: Sustained seating
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained seating force during bonding (300 g for 3 seconds, maintained for 40 seconds during curing)
Trial: 21030470
Drug: Initial seating
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial seating force (300 g for 3 seconds, no sustained force)
Trial: 26606872
Drug: Traditional swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional swallowing therapy
Trial: 17592789
Drug: Ziprasidone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80 mg/day)
Trial: 17592789
Drug: Ziprasidone (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (160 mg/day)
Trial: 17592789
Drug: Ziprasidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (mean dose)
Trial: 11588528
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg, once daily)
Trial: 11588528
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg, once daily)
Trial: 9849987
Drug: Three dose
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose primary schedule (2, 4, 6 months)
Trial: 9849987
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose primary schedule (3, 5 months)
Trial: 7851356
Drug: Neostigmine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine and methyl-atropine administered 2 minutes after rocuronium (Group B)
Trial: 7851356
Drug: Neostigmine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine and methyl-atropine administered at 25% twitch recovery (Group C)
Trial: 7851356
Drug: Neostigmine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine and methyl-atropine administered at spontaneous recovery (Group A)
Trial: 68454
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of bleomycin
Trial: 68454
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) injection of bleomycin
Trial: 26482136
Drug: Therapeutic Educational
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Educational System (TES) with Contingency Management (CM) component, earning up to $600 in prizes over 12 weeks for providing drug negative urines and completing web-based cognitive behavior therapy modules.
Trial: 25174443
Drug: Bioline® (albumin-heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioline® (albumin-heparin coating)
Trial: 23740194
Drug: Triple antioxidant
RxNorm normalized name: Ascorbic Acid/Vitamin A/Vitamin E 250 MG-5000 IU-200 IU Oral Tablet [TRIPLE ANTIOXIDANT FORMULA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antioxidant therapy (allopurinol, α-lipoic acid, and nicotinamide)
Trial: 9223025
Drug: L‐NMMA 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA 4.0 mumol/min i.v.
Trial: 9223025
Drug: L‐arg (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐arg (30 mumol/kg‐min i.v.)
Trial: 8335541
Drug: High-carbohydrate diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate diet (10 g/kg body wt)
Trial: 8335541
Drug: Moderate-carbohydrate diet
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-carbohydrate diet (5 g/kg body wt)
Trial: 2952606
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intracoronary thrombolysis with transluminal coronary angioplasty
Trial: 2952606
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intracoronary thrombolysis without transluminal coronary angioplasty
Trial: 29878035
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg vitamin D3/d (400 IU)
Trial: 29878035
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg vitamin D3/d (800 IU)
Trial: 29878035
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 µg vitamin D3/d)
Trial: 27394029
Drug: Follow-up antibody
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up antibody testing after RBC transfusions
Trial: 27394029
Drug: No follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No follow-up antibody screen or testing too soon (<30 days) after transfusion
Trial: 22340993
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 10mg/kg as a bolus preoperatively followed by 1mg/kg as a maintenance dose intra operatively
Trial: 20206835
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/day for 8 weeks
Trial: 12857764
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training program (6 months of physical therapy, strength training, and walking followed by 3 months of endurance exercise at 78% of peak heart rate)
Trial: 2003858
Drug: Ketotifen (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (6 mg/day)
Trial: 30342551
Drug: Guanxinjing capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanxinjing capsule (GXJ)
Trial: 22507611
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of daily complementary feeding
Trial: 19850529
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received pharmacotherapy (anticholinergics or desmopressin) as needed
Trial: 16203877
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg orally per week for twenty‐five weeks)
Trial: 16203877
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no medication or placebo)
Trial: 8657762
Drug: gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel containing lysated keratinocyte cultures
Trial: 8657762
Drug: placebo-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-gel
Trial: 6093960
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg
Trial: 6125203
Drug: Ranitidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 200 mg
Trial: 6118248
Drug: Ranitidine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (various doses)
Trial: 31335174
Drug: Traditional Occupational
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Occupational Therapy (TOT) intervention group
Trial: 31104833
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (oral phosphate and active vitamin D)
Trial: 17479609
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate
Trial: 11185665
Drug: Fe2+ form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe2+ form of elemental iron, 7.5 mg daily
Trial: 11185665
Drug: Nonionic trivalent
RxNorm normalized name: LANOLIN DERIVATES,NONIONIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic trivalent iron (FeIII) complexed with polysaccharides, 7.5 mg daily
Trial: 9124858
Drug: CP following
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP following oral administration of diltiazem (60 mg)
Trial: 9124858
Drug: CP following
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP following oral administration of nifedipine (20 mg)
Trial: 3893511
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2 g of sulfametopyrazine
Trial: 3893511
Drug: Ampicillin 250
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 250 mg thrice daily for 7 days
Trial: 28419732
Drug: Retosiban (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retosiban (6 mg/h infusion for 24 hours, followed by 12 mg/h infusion over the next 24 hours; preceded by a 6 mg loading dose over 5 minutes)
Trial: 24888381
Drug: Oral simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral simvastatin 40 mg at night for 12 months
Trial: 19946776
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 1,200 mg and vitamin D3 400 IU (10 microg)
Trial: 18665021
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate 160 mg IM
Trial: 16037175
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position (L group)
Trial: 1835619
Drug: Sizofiran (SPG)
RxNorm normalized name: Sizofiran
DrugBank: Sizofiran (DB13128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sizofiran (SPG) administered with antitumour drugs
Trial: 27628168
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity promotion intervention (exercise program of 1-hour sessions twice a week for a year)
Trial: 23392270
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin daily (high dose) over 3 weeks
Trial: 23392270
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin daily (normal dose)
Trial: 20674311
Drug: Resveratrol 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 30 mg
Trial: 20674311
Drug: Resveratrol 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 90 mg
Trial: 20674311
Drug: Resveratrol 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 270 mg
Trial: 21798991
Drug: One-day interval
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 17-28 hours)
Trial: 21798991
Drug: Two-day interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 41-45 hours)
Trial: 17702040
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (5,000 units, three times weekly subcutaneously)
Trial: 12225327
Drug: Consensus interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus interferon (CIFN) induction therapy for one month followed by standard 9 microg of CIFN thrice weekly for 11 months
Trial: 12225327
Drug: Rapid viral
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid viral response (RVR) during the first month of induction dosing
Trial: 12225327
Drug: Induction dosing
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dosing with CIFN
Trial: 12225327
Drug: Early viral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early viral kinetics during the first month of therapy
Trial: 15641227
Drug: Eradication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication treatment (Pantoprazole 40 mg 1x/day, Amoxycillin 1000 2x/day, Claritromycin 500 2x/day)
Trial: 8787478
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (hyperventilation, inspired oxygen fraction of 0.80, and inotropic agents)
Trial: 7440192
Drug: Heparin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (3 x 5000 IU/day)